Voyager Therapeutics 3Q 2026: Revenue $4.01M, EPS ($0.4) — 10-Q Summary
Voyager Therapeutics reported 3Q 2026 revenue of $4.01M, down 70% YoY, with a net loss of $24.69M, an 11.5% improvement. Collaboration revenue included $3.1M from Novartis and $0.5M from Neurocrine. The company reduced R&D and administrative expenses, extending its cash runway to Q2 2028.
How this was made

The 30-second read
Why it matters
The Q3 2026 results highlight a steep revenue decline but improved expense management, affecting short‑term price expectations.
Market read
Micro‑cap biotech earnings; limited immediate market impact but useful for sector‑specific risk assessment.
What to watch
Potential future cash runway into 2028 and upcoming IND/CTA clearances may support longer‑term valuation.
Background
Voyager Therapeutics is a clinical‑stage biotech focused on gene‑therapy collaborations.
Ticker impact
Voyager Therapeutics reported Q3 2026 revenue of $4.01M, a 70% YoY decline, and a narrowed net loss.
likely modest pressure as market prices in the steep revenue decline
The sharp revenue decline outweighs the slight improvement in net loss, suggesting limited upside.
Market effects
Biotech sector may see slight caution as a peer reports weak collaboration revenue.
Limited to U.S. biotech investors; no broader regional effect.
Minimal global impact given the micro‑cap size.
Counterpoint
The narrowed loss could signal improving cost discipline, offering a buying opportunity despite revenue drop.
Key entities
- companyVoyager Therapeutics, Inc.
Issuer of the 10‑Q filing.
- partnerNovartis
Provides $3.1M of the collaboration revenue.
- partnerNeurocrine
Provides $0.5M of the collaboration revenue.